Recent studies have emphasized the fundamental role of GH and insulin-like growth factor 1 (IGF-1) in the pathogenesis of MASH, suggesting their potential as therapeutic strategies to prevent the progression of MASLD to MASH [42,43]. Here, GH1 is linked to metabolic dysfunction-associated steatotic liver disease.